Analysis of therapeutic effects of GLP-1, novel anti妖iabetic medication, on non-allcoholic fatty liver disease and steatohepatitis.

点击翻译按钮获取中文摘要

The mRNA expression levels of GLP-1R and DPP-4 were quantified in the livers with NAFLD patients and compared with normal subjects. The expression levels of both genes were significantly elevated in NAFLD liver. Fatty acids induced the expression of GLP-1R in HepG2 cells. Treatment with GLP-1 in rats fed high fat diet showed suppression of body weight gain and improvement of hepatic steatosis. Markedly elevated expression of fatty acids oxidation enzymes in adipose and muscle tissues were observed in these rats, suggesting new extrapancreatic actions of GLP-1 in these tissues.